Last update: May 23, 2019

Trimebutine maleate

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Antispasmodic drug used for treatment of Irritable Colon Syndrome and in the treatment of infant and young child vomiting (Pediamecum 2015).

At latest update, no relevant published data concerning excretion into breast milk were found.

Pharmacokinetic data support the likelihood of significant excretion into breast milk.

Side effects of Trimebutine are rare and generally mild (CADTH 2015, Paquette 2014).

Authorized use in some countries during the neonatal and infant period (Pediamecum 2015, Carnot 2008).

Anticholinergic drugs may reduce milk production. Use the minimal necessary dose as possible and avoid long-term use whenever a decrease in milk production would appear.

Occasional use and at a sufficient minimum dose may be compatible with breastfeeding. Monitor drowsiness and milk production.
Do not use it soon after birth or in case of premature infant.

Alternatives

We do not have alternatives for Trimebutine maleate.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Trimebutine maleate in other languages or writings:

Group

Trimebutine maleate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Trimebutine maleate in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 504 daltons
Protein Binding 5 %
VD 1,2 l/Kg
Tmax 1 - 2 hours
T1/2 4 - 12 hours

References

  1. Comité de Medicamentos de la Asociación Española de Pediatría. Trimebutina. Pediamecum. 2015 Full text (link to original source) Full text (in our servers)
  2. CADTH. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Nov 30. Abstract
  3. Gador. Trimebutina. Ficha técnica. 2014 Full text (in our servers)
  4. Paquette JM, Rufiange M, Iovu Niculita M, Massicotte J, Lefebvre M, Colin P, Telmat A, Ranger M. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers. Clin Ther. 2014 Nov 1;36(11):1650-64. Abstract
  5. Aptalis Pharm. Trimebutine. Drug Summary. 2011 Full text (in our servers)
  6. Carnot. Libertrim pediátrico suspensión. Ficha técnica. 2008 Full text (in our servers)
  7. Jiang H, Ding L, Yang J, Huang X, Liu GY, Zhang ZX. [Pharmacokinetics and bioequivalence of trimebutine dispersive tablet in healthy subjects]. Yao Xue Xue Bao. 2004 Abstract

Total visits

85,122

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM